Provided by Tiger Fintech (Singapore) Pte. Ltd.

Capricor Therapeutics

11.25
+1.6116.70%
Post-market: 11.350.1000+0.89%19:58 EDT
Volume:1.51M
Turnover:16.45M
Market Cap:513.86M
PE:-9.79
High:11.32
Open:10.20
Low:10.20
Close:9.64
Loading ...

When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable?

Simply Wall St.
·
17 Apr

Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day

GlobeNewswire
·
01 Apr

High Growth Tech Stocks In The US Market With Promising Potential

Simply Wall St.
·
28 Mar

Capricor Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
21 Mar

Capricor Therapeutics Price Target Maintained With a $30.00/Share by Cantor Fitzgerald

Dow Jones
·
20 Mar

Q4 2024 Capricor Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
20 Mar

Stock Track | Capricor Therapeutics Soars 6.46% Pre-Market on Strong Q4 Results, Analyst Optimism, and Pipeline Progress

Stock Track
·
20 Mar

Stock Track | Capricor Therapeutics (CAPR) Soars 6.38% Pre-Market on Strong Q4 Results and Analyst Optimism

Stock Track
·
20 Mar

Piper Sandler Remains a Buy on Capricor Therapeutics (CAPR)

TIPRANKS
·
20 Mar

Capricor Therapeutics Stock (CAPR) Surges on Q4 Results and Promising New Therapy

TIPRANKS
·
20 Mar

Capricor Therapeutics Reports 2024 Financial Results

TIPRANKS
·
20 Mar

Capricor Therapeutics reports Q4 EPS (16c), consensus (9c)

TIPRANKS
·
20 Mar

Capricor Therapeutics Q4 2024 GAAP EPS $(0.16) Beats $(0.26) Estimate, Sales $11.10M Beat $5.68M Estimate

Benzinga
·
20 Mar

Capricor Therapeutics Q4 Operating Expenses USD 18.8 Million

THOMSON REUTERS
·
20 Mar

Capricor Therapeutics: Available Cash, Cash Equivalents & Marketable Securities Sufficient to Cover Expenses & Capital Requirements Into 2027

THOMSON REUTERS
·
20 Mar

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
20 Mar

While institutions own 38% of Capricor Therapeutics, Inc. (NASDAQ:CAPR), retail investors are its largest shareholders with 49% ownership

Simply Wall St.
·
19 Mar

Capricor Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
18 Mar

Capricor Therapeutics Price Target Maintained With a $77.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Mar

Capricor Therapeutics announces long-term data from HOPE-2 OLE study

TIPRANKS
·
17 Mar